TFF Pharmaceuticals Initiates Corporate Dissolution Following Shareholder Vote

Tff Pharmaceuticals US87241J1043

TFF Pharmaceuticals Inc. has formally commenced its corporate wind-down, a process set in motion by a shareholder-approved dissolution plan. This decisive move follows the company's recent delisting from the Nasdaq exchange, marking the end of its public trading chapter. The focus now shifts entirely to liquidation procedures.

The definitive step toward dissolution occurred on Monday, March 3, 2025, when a majority of shareholders voted in favor of the Plan of Dissolution. TFF Pharmaceuticals documented this approval in an 8-K filing submitted to regulators on March 6, 2025. This vote provided the necessary authorization to proceed with the systematic closure of the company's affairs.

Operational winding down began months prior. In November 2024, the company announced it would cease active business operations and terminate its workforce. Key agreements, including a patent license with the University of Texas, were concluded. To oversee the liquidation process, the Board of Trustees appointed Craig R. Jalbert as the responsible liquidating trustee.

Nasdaq Delisting Completed

Prior to the shareholder vote, TFF Pharmaceuticals executed its exit from the public markets. The company announced its voluntary delisting from the Nasdaq Capital Market in February 2025. Around February 16, 2025, it filed a Form 25 with the U.S. Securities and Exchange Commission and Nasdaq. The delisting became effective ten days after this submission.

Crucially, the firm stated it has not established any agreements to facilitate trading or listing of its common stock on an alternative exchange or quotation platform.

• Delisting announced: February 2025
• Form 25 filed: Approximately February 16, 2025
• Effective date: Ten days post-filing
• No alternative listing planned

Implications for Investors and Next Steps

With the delisting complete and liquidation underway, TFF Pharmaceuticals no longer pursues any growth or operational strategy. Its sole remaining objective is an orderly dissolution. In this context, traditional metrics for evaluating stock performance have become irrelevant. The common shares are no longer tradable on the Nasdaq, and no alternative trading venue has been arranged.

The key milestones are now clear: the delisting is finalized, shareholder consent has been granted, operational shutdown is in progress, and a liquidator is in place. The subsequent phases of the wind-down process and any actions taken by the appointed liquidator will define the final stages of the company's existence.